The FDA is scheduling renewed advisory committee activity under new leadership, with officials signaling a higher priority for contentious product applications. Two announced meetings highlight that shift: discussions involving Replimune and Capricor, along with renewed attention to peptide-related review controversies. The Replimune and Capricor agenda comes as the agency faces continued public and stakeholder scrutiny over how advisory inputs are weighed. The report also notes the upcoming sessions will effectively test whether FDA processes have changed since prior leadership controversies. For manufacturers, the message is clear: contested submissions may see more formal outside expert review, increasing the operational importance of advisory preparedness and evidence transparency.